Stock 3218 UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Universal Vision Biotechnology Co., Ltd.

Equities

3218

TW0003218004

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
240 TWD -0.21% Intraday chart for Universal Vision Biotechnology Co., Ltd. -2.64% -13.36%
Mar. 14 Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 13 Universal Vision Biotechnology Co., Ltd. Declares Cash Dividend, Payable on May 20, 2024 CI

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 57% by 2026.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • With an enterprise value anticipated at 4.02 times the sales for the current fiscal year, the company turns out to be overvalued.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. Stock Universal Vision Biotechnology Co., Ltd.
-13.36% 623M -
ESSILORLUXOTTICA Stock EssilorLuxottica
+11.95% 98.12B
B
THE COOPER COMPANIES, INC. Stock The Cooper Companies, Inc.
-6.10% 17.66B
B-
AUTEK CHINA INC. Stock Autek China Inc.
-20.02% 2.24B
D+
WARBY PARKER INC. Stock Warby Parker Inc.
-8.37% 1.54B
C+
PEGAVISION CORPORATION Stock Pegavision Corporation
+29.63% 1.23B -
MENICON CO., LTD. Stock Menicon Co., Ltd.
-35.36% 735M
B-
MINGYUE OPTICAL LENS CO.,LTD. Stock Mingyue Optical Lens Co.,Ltd.
-35.62% 747M -
VIZIONFOCUS INC. Stock Vizionfocus Inc.
+24.04% 494M - -
VISCO VISION INC. Stock Visco Vision Inc.
+17.74% 493M -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 3218 Stock
  4. Ratings Universal Vision Biotechnology Co., Ltd.